Stone Four Medicine Group (02005.HK): Remdesivir has been approved by the National Medical Products Administration for registration as an active pharmaceutical ingredient for use in listed preparations.

The Zhtng Financial APP News, Sisay Pharmaceutical Group (02005.HK) announced that its Mabaviravir has been approved by the China National Medical Products Administration for registration as an active pharmaceutical ingredient used in marketed formulations, making it the third domestic enterprise to receive this approval.